Daewoong Pharmaceutical Announces Successful 'Extra Strength' Results of US Phase 2 Clinical Trial for High-dose Administration of Botulinum Toxin

High-dose Jeuveau, with a dosage double that of the existing 20 units, has succeeded in Phase 2 clinical trials as Extra StrengthDemonstrating a proven long-term efficacy of 6 months or 26 weeks, Jeuveau enhances global product competitiveness by

Related Keywords

United States ,Chicago ,Illinois , ,Clinical Trial For Administration Of Botulinum Toxin ,American Society For Dermatologic Surgery ,High Dose Jeuveau ,Line Scale ,Post Procedure Improvement Assessment Scale ,Pharmaceutical Announces Successful ,Extra Strength Results ,High Dose Administration ,American Society ,Dermatologic Surgery ,Glabellar Line Scale ,Aesthetic Improvement Scale ,Soo Park ,Vice President ,Daewoong Pharmaceutical ,